The Hidden Price of "Progress" A recent proposal from the Centers for Medicare and Medicaid Services (CMS) aims to accelerate medical innovation by introducing new price controls on prescription drugs.
At first glance, this seems like a classic case of trying to have it both ways: supporting cutting edge research while keeping costs in check.
However, scratch beneath the surface, and you'll find that CMS's plan might do just the opposite. The key change lies in how CMS plans to determine when newer medicines become eligible for government price controls.